Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life sciences and biotech startups, today announced that Carmine Therapeutics and STIMIT are the winners of Bristol-Myers Squibb's 2019 Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life sciences and biotech startup companies per year of active sponsorship for "Golden Tickets," which underwrite the cost of one lab bench for one year in LabCentral’s Kendall Square facility.

"The Golden Ticket contest is a terrific mechanism for us to establish connections with innovative new companies emerging from the entrepreneurial community in Cambridge," said Sharon Cload, vice president, Molecular Discovery Technologies at Bristol-Myers Squibb. "This was a strong field of contestants, and we are delighted to name Carmine Therapeutics and STIMIT as the 2019 recipients. It is our hope that access to LabCentral will provide these companies with the resources and environment that will enable rapid advancement of their programs."

Carmine Therapeutics is pioneering a new class of genetic medicines based on red blood cell extracellular vesicles (RBCEVs) as redosable allogeneic therapies. These homogeneous, non-immunogenic and stable vesicles can be exogenously engineered, at scale, without culture expansion, to carry large nucleic acid payloads (at least 11 kilobases), and surface functionalized with targeting ligands to increase bioavailability in specific tissues and cell types. This technology, published in Nature Communications, forms the foundation of Carmine's fully modular and robust REGENT platform that aims to revolutionize nucleic acid therapies.

STIMIT aims to disrupt how, when and where cancer immunotherapy is deployed to dramatically improve patient outcomes. Specifically, STIMIT has developed a hydrogel from a natural, biodegradable, FDA-approved polymer to enable extended localized release of cancer immunotherapy in the context of surgical tumor resection, which is the standard of care for most cancer patients with solid tumors. While most approaches in oncology attempt to treat macroscopic disease, STIMIT is reprogramming the post-resection milieu from immunosuppressive to immunostimulatory and thereby improving the efficacy and safety of immunotherapy relative to traditional routes of administration.

"Golden Tickets afford promising early stage life sciences companies the opportunity to explore and develop their ideas in a deeply collaborative environment," said Johannes Fruehauf, M.D., Ph.D., co-founder and president, LabCentral. "The selected winners, STIMIT and Carmine Therapeutics, are creating novel technologies at the cutting-edge of advanced drug delivery platforms and we at LabCentral look forward to supporting them in reaching their next milestones. We are pleased to welcome Carmine to our community and to congratulate them and STIMIT both on receiving the Bristol-Myers Squibb Golden Ticket."

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About LabCentral

LabCentral is a first-of-its-kind shared laboratory workspace in the heart of the Kendall Square, Cambridge, biotech innovation hub, designed as a launchpad for high-potential life-sciences and biotech startups. It offers everything young companies need to begin lab operations immediately upon move-in and propel their science forward faster and more cost-efficiently. This includes: beautifully designed, fully permitted lab and office space, first-class facility and administrative support, skilled laboratory personnel, peer learning and networking opportunities, an expert speaker series - as well as critical access to potential funders and industry partners. A private, nonprofit institution, its first site opened in 2013, with support from real-estate partner, MIT. Founding sponsors include Johnson & Johnson Innovation, the Massachusetts Life Sciences Center, Roche, and Triumvirate Environmental. To accommodate demand for growing startups, LabCentral expanded its original site to double the original size in the fall of 2017, and, with support from Pfizer, opened LabCentral 610 at the end of the year. LabCentral now has capacity to serve a total of ~450 scientists and entrepreneurs in about 70 companies across its two-building campus. In 2017, it also added the LabCentral Learning Lab for STEM programming to help inspire the next generation of science entrepreneurs.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...